News
Scientific Updates from MTTLab
Latest results from our ongoing projects, new publications from our team and updates on collaborations across oncology, CNS and inflammation research.
Syngeneic Model Validation for Anti-PD-1 Combination Studies in Colorectal Cancer
Our team published validation data for the CT26 and MC38 syngeneic platforms used in immuno-oncology combination regimens, with a focus on reproducibility and PD endpoint standardisation. Journal of Translational Medicine, 2025.
Request reprint →PK/PD Programme Completed for Novel ALK Inhibitor in NSCLC PDX Model
Successful completion of a 12-week IND-enabling PK/PD programme for a next-generation ALK inhibitor. Full NCA and compartmental modelling delivered with regulatory-ready reporting. Partner proceeding to Phase I.
Discuss a similar study →Neuroinflammation Biomarker Panel for Rotenone-Induced Parkinson’s Model: Cross-Laboratory Validation
Multi-centre validation of a 12-plex cytokine and neurodegeneration biomarker panel developed for use in the rotenone rat model of Parkinson’s disease. Accepted as a reference dataset for consortium studies. Neuropharmacology, 2024.
Request reprint →MTTLab Joins European Preclinical Network for Inflammatory Bowel Disease Research
MTTLab has been selected as a core laboratory partner in a pan-European consortium investigating novel therapeutic targets in IBD. We contribute DSS-colitis model expertise and multiplex cytokine profiling capabilities to the consortium platform.
Learn about our inflammation work →Stay Updated on Our Research
Want to receive new publication alerts and project updates directly? Get in touch and we will add you to our scientific newsletter.
Subscribe to updates